Sarepta’s Exon-skipping Drugs Have Key Role Treating DMD
What is the outlook for Sarepta Therapeutics’ exon-skipping drugs if the FDA rejects or does not expand the indications for Sarepta’s new gene therapy treatment for Duchenne muscular dystrophy?
Report Date :
Sarepta Therapeutics Inc.
Source Silos :
- Physicians treating DMD with Sarepta products.
- DMD treatment sales professionals.
4516: T, PFE, SRPT
Health Care Equipment and Supplies